

```

<!--StartFragment-->RESULT 3
AAM49641
ID      AAM49641 standard; protein; 836 AA.
XX
AC      AAM49641;
XX
DT      15-JUN-2007 (revised)
DT      17-MAY-2002 (first entry)
XX
DE      Human tumour-associated antigen B345 protein SEQ ID NO 4.
XX
KW      Tumour-associated antigen; human; B345; cytostatic; cell communication;
KW      cell interaction; signal transduction; metastasis; cancer; colon;
KW      immunotherapy; carcinoma; lung; diagnosis; BOND_PC;
KW      CUB domain containing protein 1, isoform CRA_a;
KW      CUB domain containing protein 1, isoform CRA_a [Homo sapiens];
KW      CUB domain containing protein 1;
KW      CUB domain containing protein 1 [Homo sapiens]; GO5194; GO6942; GO7517;
KW      GO8307; GO16020; GO16021.
XX
OS      Homo sapiens.
XX
PN      WO200204508-A1.
XX
PD      17-JAN-2002.
XX
PF      05-JUL-2001; 2001WO-EP007705.
XX
PR      07-JUL-2000; 2000DE-01033080.
PR      19-APR-2001; 2001DE-01019294.
XX
PA      (BOEH ) BOEHRINGER INGELHEIM INT GMBH.
XX
PI      Schweifer N, Scherl-Mostageer M, Sommergruber W, Abseher R;
XX
DR      WPI; 2002-171704/22.
DR      N-PSDB; ABA99507.
DR      PC:NCBI; g114328879.
DR      PC:SWISSPROT; Q9H5V8.
XX
PT      New tumor-associated antigen B345, useful for diagnosis and immunotherapy
PT      of tumors, also related nucleic acid and antibodies.
XX
PS      Claim 1; Page 85-88; 102pp; German.
XX
CC      This invention describes a novel tumour-associated antigen, designated
CC      B345 which has cytostatic activity. B345 is involved in communication,
CC      interaction and/or signal transduction with extracellular components and
CC      ligands, especially in the metastatic potential of cancers, particularly
CC      of the colon. B345 or its immunogenic fragments, also the DNA that
CC      encodes it, are useful for immunotherapy of cancer, particularly
CC      carcinoma of lung or colon. Antibodies raised against B345 are useful for
CC      treatment and diagnosis of cancers that are associated with B345
CC      expression, including their use for targeted delivery of cytotoxic or
CC      radioactive agents. Probes derived from B345 can be used to detect tumour
CC      -specific mutations in the B345 sequence, and can be used to screen for
CC      B345 specific modulators. This sequence represents a human B345 tumour-
CC      associated antigen described in the invention
CC
CC      Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC      information from BOND.

```

XX

SQ Sequence 836 AA;

Query Match 99.8%; Score 4387; DB 5; Length 836;  
 Best Local Similarity 99.9%; Pred. No. 0;  
 Matches 835; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy      1  MAGLNCVGSIALLGVLLLGAARLPRGAEEAFIALPRESNITVLIKLGTPTLLAKPCYIVI 60
      |||
Db      1  MAGLNCVGSIALLGVLLLGAARLPRGAEEAFIALPRESNITVLIKLGTPTLLAKPCYIVI 60

Qy     61  SKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMGSPCPFGEVQLQPSTSLPT 120
      |||
Db     61  SKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMGSPCPFGEVQLQPSTSLPT 120

Qy    121  LNRTFIVDWKAHKSIGLELQFSIPRLRQIGPGESCPOGVTHSISGRIDATVVRIGTFCSN 180
      |||
Db    121  LNRTFIVDWKAHKSIGLELQFSIPRLRQIGPGESCPOGVTHSISGRIDATVVRIGTFCSN 180

Qy    181  GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY 240
      |||
Db    181  GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY 240

Qy    241  PEGFPEDELMTWQFVVPFAHLRASVSFLNFNLSNCERKEERVEYIIPGSTTNEPVFKLEDK 300
      |||
Db    241  PEGFPEDELMTWQFVVPFAHLRASVSFLNFNLSNCERKEERVEYIIPGSTTNEPVFKLEDK 300

Qy    301  QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE 360
      |||
Db    301  QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE 360

Qy    361  PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVKTIISCTDH 420
      |||
Db    361  PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVKTIISCTDH 420

Qy    421  RYCQRKSYSLQVPSDILHLPVELHDFSWKLLVPKDRLSLVLPQAQLQQTHTHEKPCNTSF 480
      |||
Db    421  RYCQRKSYSLQVPSDILHLPVELHDFSWKLLVPKDRLSLVLPQAQLQQTHTHEKPCNTSF 480

Qy    481  SYLVASAIPSQDLYFGSFCPGGSIKIQVKQNISVTLRTFAPSQQEASRQGLTVSFIPY 540
      |||
Db    481  SYLVASAIPSQDLYFGSFCPGGSIKIQVKQNISVTLRTFAPSQQEASRQGLTVSFIPY 540

Qy    541  FKEEGVTVTPDTKSKVYLRTPNWDRGLPSLTSVSNISVPRDQVACLTFKERSGVVCQ 600
      |||
Db    541  FKEEGVTVTPDTKSKVYLRTPNWDRGLPSLTSVSNISVPRDQVACLTFKERSGVVCQ 600

Qy    601  TGRAFMIIQEQRTRAEEIFSLDEDVLPKPSFHHSFVWVNISNCSPTSGKQLDLLFVSTLT 660
      |||
Db    601  TGRAFMIIQEQRTRAEEIFSLDEDVLPKPSFHHSFVWVNISNCSPTSGKQLDLLFVSTLT 660

Qy    661  PRTVDLTVLIIAAVGGGVLLLSALGLIICCVKKKKKTKNGKPAVGVIYNDINTEMPRQPK 720
      |||
Db    661  PRTVDLTVLIIAAVGGGVLLLSALGLIICCVKKKKKTKNGKPAVGVIYNDINTEMPRQPK 720

Qy    721  KFQKGKDKNDSHVYAVIEDTMVYGHLQDSSGSFLQPEVDTRYFQGTMGVCPSPPTIC 780
      |||
Db    721  KFQKGKDKNDSHVYAVIEDTMVYGHLQDSSGSFLQPEVDTRYFQGTMGVCPSPPTIC 780

Qy    781  SRAPTAKLATEEPPRSPPESESEPYTFSHPNNGDVSSKDDTIDPLNTQEPMEPAE 836
      |||

```

Db 781 SRAPTAKLATEEPPRSPPESESEPYTFSHPNNGDVSSKDTDIPLLTQEPMEPAE 836  
<!--EndFragment-->